FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease
The primary endpoint of the study was clinical remission at week 52 with vedolizumab
The primary endpoint of the study was clinical remission at week 52 with vedolizumab
ClinicalTrials.gov Identifier: NCT05143047.
Currently, the treatment is being evaluated in the phase 3 CALYPSO study to further prove the safety and efficacy in patients with hypoparathyroidism.
How to use this guide and why antimicrobial stewardship is important for nursing homes.
This cross-sectional study investigates the association between day-to-day changes in telemedicine share and clinician time spent on electronic health record (EHR) use.
AHRQ advances excellence in healthcare by producing evidence to make healthcare safer, higher quality, more accessible, equitable, and affordable.
The fourth edition of the AHRQ publication, “Registries for Evaluating Patient Outcomes: A User’s Guide,” is a reference handbook that provides best practices to guide…
The purpose of this Challenge Competition is to solicit ideas on the future state of CDS Connect.
Venture capital investments in women’s health are growing, with innovation looking beyond traditional avenues.